AB
RNAC icon

Amalgamated Bank’s Cartesian Therapeutics RNAC Stock Holding History

Amalgamated Bank’s Portfolio RNAC Stock Details RNAC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-330
Closed -$2K – 2577
2025
Q4 		$2K Sell
330
-26
-7% -$210 ﹤0.01% 2919
2025
Q3 		$4K Hold
356
– – ﹤0.01% 2857
2025
Q2 		$4K Hold
356
– – ﹤0.01% 2869
2025
Q1 		$5K Buy
356
+226
+174% +$4.04K ﹤0.01% 2687
2024
Q4 		$2K Hold
130
– – ﹤0.01% 2917
2024
Q3 		$2K Hold
130
– – ﹤0.01% 2944
2024
Q2 		$4K Sell
130
-1
-0.8% -$24 ﹤0.01% 2879
2024
Q1 		$3K Sell
131
-261
-67% -$5.53K ﹤0.01% 2844
2023
Q4 		$8K Sell
392
-39
-9% -$1.16K ﹤0.01% 2902
2023
Q3 		$14K Hold
431
– – ﹤0.01% 2819
2023
Q2 		$14K Buy
+431
New +$15.4K ﹤0.01% 2893
2022
Q2 		– Sell
-385
Closed -$14K – 3173
2022
Q1 		$14K Sell
385
-26
-6% -$1.63K ﹤0.01% 2900
2021
Q4 		$40K Sell
411
-7
-2% -$753 ﹤0.01% 2118
2021
Q3 		$52K Sell
418
-16
-4% -$1.93K ﹤0.01% 2131
2021
Q2 		$54K Buy
+434
New +$51.7K ﹤0.01% 2159

Other funds holding RNAC

Squarepoint
Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Amalgamated Bank's RNAC Position: Q1 2026 in Review

Amalgamated Bank sold out of Cartesian Therapeutics (RNAC) in Q1 2026, closing a stake of 330 shares — an estimated $2K sold.

Amalgamated Bank first reported a position in RNAC in Q2 2021 and held it in 15 quarters. The position peaked at $54K in Q2 2021. 83 funds tracked by Wall St. Rank hold RNAC as of Q1 2026.

  • Amalgamated Bank reported no remaining Cartesian Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Amalgamated Bank sold 330 Cartesian Therapeutics shares in Q1 2026, an estimated $2K.
  • Amalgamated Bank first reported a position in Cartesian Therapeutics in Q2 2021 and held it in 15 quarters.
  • Amalgamated Bank's Cartesian Therapeutics position peaked at $54K in Q2 2021.
  • 83 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q1 2026.

Based on Amalgamated Bank's 13F filing for Q1 2026, filed 8 May 2026.